Morrow Sodali appoints Charles A. Koons as Managing Director, Activism & Contested Situations Advisory Group
05 September 2017 Press Releases
Charles A. Koons has joined Morrow Sodali as Managing Director of its Activism & Contested Situations Advisory Group. Charlie will provide strategic counsel to clients on a variety of shareholder-related issues, with particular emphasis on activist situations and proxy fights.
Charlie brings more than 20 years of experience as a senior advisor in shareholder activism and contested M&A, providing high-level advice to both corporate issuers as well as shareholders, most recently as Managing Director of MacKenzie Partners. Charlie’s extensive track record includes engagements across the full spectrum of transactions, including some of the most notable proxy fights of recent years.
“Charlie’s addition to the Morrow Sodali team represents a significant strengthening of our capabilities in the contested situations arena that we are dealing with in many markets across the world. We are extremely pleased to have someone with his experience, skills and judgment to advise clients and work in close coordination with legal, financial and public relations advisors in these fast-moving engagements,” said Alvise Recchi, CEO of Morrow Sodali.
“Companies today are faced with escalating pressure from their shareholders on a number of fronts, ranging from corporate governance policies to business operations. Our Activism & Contested Situations Advisory Group helps clients effectively anticipate, prepare and respond to shareholder demands by providing strategic guidance in these highly charged and critical situations,” added Ron Knox, CEO, of Morrow Sodali US.
Read the entire Press Release by downloading the attachment below.
Related News
Sodali & Co Shortlisted for Multiple Transform Awards ANZ 2025
01 October 2025
Sodali & Co Shortlisted for Strategic Comms Agency of the Year
01 October 2025
Sodali & Co Celebrates Excellence in Financial PR
31 August 2025
How to Prep a CEO For the Scrutiny of Life Post-IPO: ECM Watch
25 August 2025
Media enquiries
To contact our global experts for comments please get in touch below.
Contact us chevron_right